Recursion Pharmaceuticals
RXRX
RXRX
335 hedge funds and large institutions have $1.61B invested in Recursion Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 138 increasing their positions, 69 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
2.41% less ownership
Funds ownership: 79.42% → 77.01% (-2.4%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
22% less capital invested
Capital invested by funds: $2.06B → $1.61B (-$451M)
Holders
335
Holding in Top 10
9
Calls
$28.3M
Puts
$21.7M
Top Buyers
| 1 | +$22M | |
| 2 | +$13.6M | |
| 3 | +$13.1M | |
| 4 |
Morgan Stanley
New York
|
+$11.4M |
| 5 |
KA
Kinnevik AB
Stockholm,
Sweden
|
+$8.09M |
Top Sellers
| 1 | -$52.2M | |
| 2 | -$15.6M | |
| 3 | -$9.11M | |
| 4 |
LCM
Laurion Capital Management
New York
|
-$4.81M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.54M |